Literature DB >> 29928435

Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma.

Min-Ke He1,2, Yong Le1,2, Yong-Fa Zhang1,2, Han-Yue Ouyang1,2,3, Pei-En Jian1,2, Zi-Shan Yu1,2, Li-Juan Wang1,2, Ming Shi1,2,3.   

Abstract

Hepatocellular carcinoma (HCC) is among the most fatal types of cancer worldwide due to its high rates of recurrence and metastasis. The molecular processes involved in HCC progression require further investigation to identify biomarkers for use in diagnosis and treatment. In the present study, the significance and prognostic value of matrix metallopeptidase 12 (MMP12) expression in human HCC was investigated. MMP12 mRNA expression was investigated using reverse transcription-quantitative polymerase chain reaction analysis of 42 pairs of tumor and non-tumor liver tissues obtained from patients with HCC following surgical treatment. Immunohistochemical staining was used to detect MMP12 and forkhead box P3 (FOXP3) expression in 158 paraffin-embedded HCC tissues. The prognostic value of MMP12 expression was determined using Kaplan-Meier analysis and the Cox proportional hazards model. MMP12 mRNA levels were significantly higher in liver tumor tissues compared with matched non-tumor liver tissues. MMP12 expression and FOXP3+ regulatory T cell (Treg) infiltration was positively correlated (r=0.302; P<0.001). MMP12 protein overexpression was positively correlated with tumor size (P=0.018), high serum alpha-fetoprotein levels (P=0.005) and poor overall survival time (P=0.012) in patients with HCC. Furthermore, MMP12 protein level was an independent predictive factor for overall survival time of patients with HCC who underwent curative resection. In conclusion, these results suggest that MMP12 may increase FOXP3+ Treg infiltration into tumor tissues, and promote tumor progression and immune evasion of HCC. The overexpression of MMP12 protein is, therefore, a valuable prognostic indicator in patients with HCC.

Entities:  

Keywords:  forkhead box P3; human hepatocellular carcinoma; matrix metalloproteinase 12; prognosis

Year:  2018        PMID: 29928435      PMCID: PMC6006382          DOI: 10.3892/ol.2018.8642

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

Review 4.  Matrix metalloproteinases and the regulation of tissue remodelling.

Authors:  Andrea Page-McCaw; Andrew J Ewald; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

5.  Cell interactions in the induction of tolerance: the role of thymic lymphocytes.

Authors:  R K Gershon; K Kondo
Journal:  Immunology       Date:  1970-05       Impact factor: 7.397

6.  Human macrophage metalloelastase worsens the prognosis of pancreatic cancer.

Authors:  Peter Balaz; Helmut Friess; Yasuo Kondo; Zhaowen Zhu; Arthur Zimmermann; Markus W Büchler
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

9.  A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays.

Authors:  Wei Huang; Kenneth Hennrick; Sally Drew
Journal:  Hum Pathol       Date:  2012-08-31       Impact factor: 3.466

10.  The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese.

Authors:  Yan Li; Jing-Hui Jia; Shan Kang; Xiao-Juan Zhang; Jian Zhao; Na Wang; Rong-Miao Zhou; Dong-Lan Sun; Ya-Nan Duan; Dong-Jie Wang
Journal:  Int J Gynecol Cancer       Date:  2009-01       Impact factor: 3.437

View more
  8 in total

1.  Epigenetic aberrations of gene expression in a rat model of hepatocellular carcinoma.

Authors:  Cayla Boycott; Megan Beetch; Tony Yang; Katarzyna Lubecka; Yuexi Ma; Jiaxi Zhang; Lucinda Kurzava Kendall; Melissa Ullmer; Benjamin S Ramsey; Sandra Torregrosa-Allen; Bennett D Elzey; Abigail Cox; Nadia Atallah Lanman; Alisa Hui; Nathaniel Villanueva; Aline de Conti; Tao Huan; Igor Pogribny; Barbara Stefanska
Journal:  Epigenetics       Date:  2022-05-03       Impact factor: 4.861

2.  Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment.

Authors:  Guoying Ni; Xiaodan Yang; Junjie Li; Xiaolian Wu; Ying Liu; Hejie Li; Shu Chen; Conor E Fogarty; Ian H Frazer; Guoqiang Chen; Xiaosong Liu; Tianfang Wang
Journal:  Clin Transl Immunology       Date:  2021-08-17

3.  Transcriptomic and microRNA Expression Profiles Identify Biomarkers for Predicting Neo-Chemoradiotherapy Response in Esophageal Squamous Cell Carcinomas (ESCC).

Authors:  Jian Wang; Pengyi Yu; Judong Luo; Zhiqiang Sun; Jingping Yu; Jianlin Wang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  Comprehensive Analysis of Prognostic Value and Immune Infiltration of MMP12 in Esophageal Squamous Cell Carcinoma.

Authors:  Jing-Tao Mao; Qiang Lu; Peng-Yu Jing; Zi-Liang Li; Xiao-Qi Yang; Ji-Peng Zhang; Zhe Li
Journal:  J Oncol       Date:  2022-02-27       Impact factor: 4.375

5.  Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma.

Authors:  Baifeng Qian; Haozhong Lin; Tian Lan; Muqi Li; Xiwen Wu; Shuirong Lin; Zimin Song; Shunli Shen; Baogang Peng
Journal:  World J Surg Oncol       Date:  2022-08-05       Impact factor: 3.253

Review 6.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

Review 7.  The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.

Authors:  Cristian Scheau; Ioana Anca Badarau; Raluca Costache; Constantin Caruntu; Gratiela Livia Mihai; Andreea Cristiana Didilescu; Carolina Constantin; Monica Neagu
Journal:  Anal Cell Pathol (Amst)       Date:  2019-11-26       Impact factor: 2.916

8.  Definition of a novel vascular invasion-associated multi-gene signature for predicting survival in patients with hepatocellular carcinoma.

Authors:  Bo Yi; Caixi Tang; Yin Tao; Zhijian Zhao
Journal:  Oncol Lett       Date:  2019-11-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.